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Abstract
Background: A localized hypoxic environment occurs during tumor growth necessitating an
angiogenic response or tumor necrosis results. Novel cancer treatment strategies take advantage
of tumor-induced vascularisation by combining standard chemotherapeutic agents with
angiogenesis-inhibiting agents. This has extended the progression-free interval and prolonged
survival in patients with various types of cancer. We postulated that the expression levels of
angiogenesis-related proteins from various primary tumor cultures would be greater under
hypoxic conditions than under normoxia.
Methods: Fifty cell sources, including both immortalized cell lines and primary carcinoma cells,
were incubated under normoxic conditions for 48 hours. Then, cells were either transferred to a
hypoxic environment (1% O2) or maintained at normoxic conditions for an additional 48 hours.
Cell culture media from both conditions was collected and analyzed via an ELISA-based assay to
determine expression levels of 11 angiogenesis-related factors: VEGF, PDGF-AA, PDGF-AA/BB, IL-
8, bFGF/FGF-2, EGF, IP-10/CXCL10, Flt-3 ligand, TGF-β1, TGF-β2, and TGF-β3.
Results:  A linear correlation between normoxic and hypoxic growth conditions exists for
expression levels of eight of eleven angiogenesis-related proteins tested including: VEGF, IL-8,
PDGF-AA, PDGF-AA/BB, TGF-β1, TGF-β2, EGF, and IP-10. For VEGF, the target of current
therapies, this correlation between hypoxia and higher cytokine levels was greater in primary
breast and lung carcinoma cells than in ovarian carcinoma cells or tumor cell lines. Of interest,
patient cell isolates differed in the precise pattern of elevated cytokines.
Conclusion: As linear correlations exist between expression levels of angiogenic factors under
normoxic and hypoxic conditions in vitro, we propose that explanted primary cells may be used to
probe the in vivo hypoxic environment. Furthermore, differential expression levels for each sample
across all proteins examined suggests it may be possible to build a predictor for angiogenesis-
related anticancer agents, as each sample has a unique expression profile. Further studies should
be performed to correlate in vitro protein expression levels of angiogenesis-related factors with in
vivo patient response.
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Background
As a tumor grows, the existing blood supply becomes inef-
ficient at supporting the tissue, and areas of the tumor
become hypoxic. The hypoxic condition triggers the
tumor to enhance the expression of angiogenic factors,
triggering the formation of new blood vessels to support
the growing tissue [1,2]. Angiogenesis is required for
tumor survival as well as further growth, progression and
metastasis [3]. In fact, high tumor vascular density is cor-
related with negative patient outcomes, including shorter
progression-free interval and reduced overall survival
[1,4,5].
One angiogenic factor whose expression is induced in
response to a hypoxic environment is vascular endothelial
growth factor (VEGF). VEGF belongs to the cystine-knot
family of growth factors [4]. Four homologous polypep-
tides for VEGF exist, derived by alternative splicing of
mRNA [2]. VEGF is secreted by cancer cells as well as sup-
porting stromal cells, including fibroblasts, especially dur-
ing conditions of hypoxia [1]. In vitro studies have shown
that stromal cells cultured in hypoxic growth conditions
secrete higher levels of critical angiogenesis-inducing fac-
tors than cells cultured in normoxic conditions [3]. High
expression of VEGF is observed in many tumor types and
is correlated with aggressive tumor growth and metastasis
[5-7].
Regulation of VEGF is complex, occurring at both the tran-
scription and translation stages of protein synthesis, with
many ligand-receptor interactions [2,3,8]. Expression of
VEGF is up-regulated by hypoxia inducible factor-1 (HIF-
1), which binds to the VEGF promoter, increasing tran-
scription of VEGF [9,10]. Once expressed, VEGF has the
ability to bind to two endothelial cell-specific receptors,
kinase domain receptor (KDR, VEGFR2) and fms-like
tyrosine kinase (Flt-1, VEGFR1) to initiate angiogenesis
among other survival signals [4,11]. While VEGF binds to
Flt-1 with 50-fold higher affinity, KDR binding is more
important for angiogenic responses [4]. Brogi et al. found
hypoxia induced a 13-fold increase in the number of KDR
receptors per endothelial cell in vitro, which may be the
mechanism of action for the pronounced effect of hypoxia
and VEGF in vivo [12]. In addition to simulating endothe-
lial cell proliferation and migration, VEGF increases vas-
culature permeability, earning its other name as vascular
permeability factor (VPF) [8,10,13]. This vascular leakage
is critical for initiating angiogenesis as it allows proteins,
such as matrix metalloproteases (MMPs), to be deposited
in the extracellular fluid [9]. MMPs break down the extra-
cellular matrix to enable endothelial cells to migrate and
invade areas in close proximity to the tumor [9].
In addition to VEGF, a number of cytokines, chemokines,
and growth factors are involved in angiogenesis. The
eleven factors tested in this study, summarized in Table 1,
were chosen because of their implication in altering vas-
cular structure and the availability of Enzyme-Linked
ImmunoSorbent Assays (ELISAs) for quantitative meas-
urement. These angiogenesis-related factors fall into a
number of general categories. Some work by mediating
VEGF production, such as basic Fibroblast Growth Factor
Table 1: Description and role of angiogenesis-related factors.
Angiogenesis-Related Factor Role in Angiogenesis
Vascular Endothelial Growth Factor/Vascular 
Permeability Factor 
(VEGF/VPF)
Signalling protein for angiogenesis that works by binding, dimerizing, and 
phosphorylating external tyrosine kinase receptors. Can be induced by hypoxia 
through the release of Hypoxia Inducible Factor (HIF) [4,6,8,10,13].
Basic Fibroblast Growth Factor 
(bFGF/FGF-2)
Stimulates production of basement membranes via formation of extracellular 
matrix. Aids in angiogenesis in tumors by mediating VEGF production [6,11,14].
Interleukin-8 
(IL-8/CXCL8)
A chemokine that regulates angiogenesis by promoting survival of endothelial 
cells, stimulating matrix metalloproteinases, and increasing endothelial 
permeability [15,16].
Epidermal Growth Factor 
(EGF)
Factor commonly expressed in carcinomas involved in tumor growth, 
proliferation, and differentiation by stimulation of intrinsic protein-tyrosine kinase 
activity, resulting in DNA synthesis. Also, induces VEGF, IL-8, and bFGF release 
by tumor cells [9,19].
Fms-related Tyrosine Kinase
(Flt-3 Ligand)
Cytokine that assists in proliferation and maturation of hematopoietic progenitor 
cells [20].
Platelet-derived Growth Factors
(PDGF-AA, -AA/BB)
Mitogenic factors for fibroblasts, smooth muscle, and connective tissue that can 
be induced by VEGF and bFGF. Induce endothelial cell survival by recruiting 
stromal cells for VEGF production [9,17].
Interferon-gamma-inducible Protein 10 
(IP-10)
Inhibits tumor growth by regulating lymphocyte chemotaxis and inhibiting 
endothelial cell growth. Down-regulation correlated with poor prognosis. 
Reverse-correlated with VEGF [21].
Transforming Growth Factors 
(TGF-β1,2,3)
Cytokines that control several biological processes including cell growth, 
proliferation, differentiation, and apoptosis. Pathological conditions such as cancer 
are can be linked to modifications of these growth factors [18].Cancer Cell International 2008, 8:11 http://www.cancerci.com/content/8/1/11
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(bFGF/FGF-2) and Epidermal Growth Factor (EGF)
[6,9,11,14]. Others work by modifying the extracellular
environment of the tumor, including bFGF, Interleukin-8
(IL-8/CXCL8), and Platelet-derived Growth Factors-AA
and -AA/BB (PDGFs) [6,15-17]. Induction of endothelial
cell growth is accomplished by IL-8, Fms Related Tyrosine
Kinase (Flt-3 Ligand), and PDGFs, while EGF and Trans-
forming Growth Factors-β1,  β2, and β3 (TGFs) are
involved in tumor growth and proliferation [9,15,18-20].
Lastly, IP-10/CXCL10 inhibits tumor and endothelial cell
growth and is inversely correlated with VEGF production
[21].
VEGF production by tumor cells is of particular interest as
this growth factor is being targeted by new anticancer
agents. Specifically, Bevacizumab (Avastin®, Genentech) is
a recombinant humanized monoclonal antibody,
approved for the treatment of colorectal cancer and non-
small cell lung cancer treatment by the FDA [5,7,22]. This
drug binds VEGF with high specificity, neutralizing the
growth factor and preventing the interaction of VEGF with
its receptors. Therefore, proliferation of endothelial cells
is inhibited and tumor progression is hindered [8,11].
Based on physiological in vivo conditions, it was hypothe-
sized that cells grown in a hypoxic in vitro environment
will express angiogenic factors, including VEGF, at higher
levels than those grown under normoxic conditions. A
secondary goal of this study was to determine whether pri-
mary tumors exhibit differential expression of angiogenic-
related factors, a phenomenon which may be useful in
predicting patient response to anti-angiogenic anticancer
agents.
Methods
Primary cell cultures
Primary cell cultures were established using tumor speci-
mens procured for research purposes from the following
sources: National Disease Research Interchange (NDRI)
(Philadelphia, PA), Cooperative Human Tissue Network
(CHTN) (Philadelphia, PA), Forbes Regional Hospital
(Monroeville, PA), Jameson Hospital (New Castle, PA),
Saint Barnabas Medical Center (Livingston, NJ), Hamot
Medical Center (Erie, PA), and Windber Research Institute
(Windber, PA). Upon receipt, all specimens were minced
to a fine consistency with Cincinnati Surgical #10 or #11
scalpels (PGC Scientifics, Frederick, MD), followed by
antibiotic washes, as necessary. In order to establish pri-
mary cultures, the specimens were typically divided into
25 cm2 and/or 75 cm2 Cellstar® sterile tissue culture flasks
with filtered caps (PGC Scientifics, Frederick, MD),
depending on the desired seeding density. Cell culture
media were tumor type specific: breast tumors were cul-
tured in Mammary Epithelial Growth Media (MEGM;
Lonza Bio Science Walkersville, Walkersville, MD), ovar-
ian tumors were cultured in McCoy's 5A growth media
(Mediatech, Herndon, VA), lung tumors were cultured in
Bronchial Epithelial Growth Media (BEGM; Lonza Bio
Science Walkersville), and colon tumors were cultured in
RPMI 1640 growth media (Mediatech). The amount of
Fetal Bovine Serum (FBS; HyClone, Logan, UT) present in
the media was also tumor-type specific, as was the pres-
ence of PureCol™ collagen (Inamed Biomaterials, Fre-
mont, CA) on the culture surface. Antibiotic washes and
antibiotic media were formulated with Penicillin-Strepto-
mycin Solution (Mediatech), Gibco Gentamicin Reagent
Solution (Invitrogen Corporation, Grand Island, NY),
Fungisone (Invitrogen), Cipro®  I.V. (ciprofloxacin)
(Oncology Therapeutics Network, South San Francisco,
CA), and Nystatin (Sigma-Aldrich, St. Louis, MO). Other
reagents include Trypsin EDTA (0.25%) and Hanks Buff-
ered Saline Solution with and without Calcium and Mag-
nesium (HBSS) (Mediatech).
All cultures were initially established in humidified incu-
bators at 37°C with 5% CO2 for 5 to 28 days. When a con-
fluency of at least 30 percent was attained, cells were
trypsinized, counted, and plated as described below.
Established cell lines
Three human tumor-derived immortalized cell lines were
also tested in this study: SK-OV-3, ovarian adenocarci-
noma; MDA-MB-231, mammary adenocarcinoma; and
A549, lung carcinoma (American Type Culture Collec-
tion, Manassas, VA). These cell lines were seeded at
50,000 cells per 5 ml in T25 flasks and allowed to grow for
one week to approximately 90% confluency. At that time,
the cells were trypsinized, counted, and plated as
described below.
Testing conditions
After the initial culture period, a total of fifty samples (45
primary cultures and 5 cell line samples) were trypsinized,
counted, and suspended in culture media to a concentra-
tion of 40,000 cells/ml. SK-OV-3 was tested on three sep-
arate occasions to ensure consistency of results. Each of
the samples was plated at 20,000 cells/well into one well
of two separate Greiner 24-well culture plates (CLP Molec-
ular Biology, San Diego, CA). Both plates were main-
tained under normoxic conditions (5% CO2 and 21% O2)
for 48 hours to allow for cell adherence and equilibration.
After 48 hours, one plate remained in normoxic condi-
tions while the other plate was transferred to a NAPCO
Series 8000WJ Water Jacketed CO2  Incubator (Ther-
moFisher Scientific, Waltham, MA) where hypoxic condi-
tions were established. Nitrogen gas was injected to purge
the incubator of oxygen resulting in a final O2 concentra-
tion of 1% while the CO2 concentration was maintained
at 5%, as described by Mukherjee et al. [3]. Plates were
incubated for an additional 48 hours. At the end of theCancer Cell International 2008, 8:11 http://www.cancerci.com/content/8/1/11
Page 4 of 9
(page number not for citation purposes)
incubation period, the confluency for each sample was
recorded and the supernatant was collected and stored at
-80°C. Confluency is the percentage of substrate with
adherent cell growth, determined subjectively by a trained
technician.
ELISA
Collected supernatants were sent to Millipore Corpora-
tion (Temecula, CA) for protein evaluation via the Bead-
lyte® CytokineProfiler™ Testing Service, an ELISA-based
assay. Evaluated angiogenesis-related cytokines and
growth factors included: VEGF, PDGF-AA, PDGF-AA/BB,
IL-8, bFGF, EGF, IP-10, Flt-3 ligand, TGF-β1, TGF-β2, and
TGF-β3. Additionally, RANTES (Regulated upon Activa-
tion, Normal T-cell Expressed, and Secreted), an analyte
not related to angiogenesis, was tested as a negative con-
trol for a subset of samples [23]. For each analyte, two rep-
licates were performed using 40 μl of supernatant per
replicate.
Statistical analysis
For each analyte, protein expression levels in the nor-
moxic and hypoxic conditions of all samples were com-
bined into a scatter plot. Then, a linear regression of the
curve fit for protein concentration under the hypoxic ver-
sus normoxic condition was generated for each analyte
tested. For all linear regressions, y = mx+b, y is the concen-
tration produced in the hypoxic environment and x is the
concentration produced in the normoxic condition. From
this regression, the slope, intercept, and correlation of
determination (r2) were calculated. The strength of each
linear relationship was determined by the r2 value of the
linear regression, with r2 values greater than 0.8 consid-
ered strong relationships, and r2 values between 0.6 and
0.8 considered moderate relationships. The same parame-
ters were used to assess VEGF expression levels by tumor
type. Lastly, comparisons were generated between the
eleven angiogenesis-related factors studied for every cell
source. The differences between the protein expression
levels under the hypoxic condition versus the normoxic
condition were calculated. This value was standardized on
a scale of zero to one, with zero set equal to the lowest
value observed and one set equal to the highest value
observed. These values were graphed as a heat map for all
samples across all factors. Additionally, Pearson correla-
tion coefficients were calculated for each factor in relation
to VEGF expression using the standardized differences
between the hypoxic and normoxic expression levels.
Results
Patient specimens and cell lines
The study included fifty distinct cell populations. Forty-
five primary tumor specimens were designated based on
final pathology and site of tumor origin including: 10
breast, 15 lung, 13 ovary, 3 colon, 3 central nervous sys-
tem (CNS), and 1 unknown primary. Additionally, five
cell line samples were tested including: A549, one sample;
MDA-MB-231, one sample; and SK-OV-3, three samples.
All samples were evaluated under both normoxic and
hypoxic environments in parallel. A strong linear relation-
ship for the confluency of the normoxic versus hypoxic
condition existed across all samples, with a linear regres-
sion of y = 0.9917x-1.516 (r2 = 0.8943; Figure 1).
Hypoxia-induced expression of angiogenesis-related 
factors
Moderate to strong linear relationships of the protein
expression levels between hypoxic and normoxic condi-
tions were observed in eight of the eleven angiogenesis-
related factors analyzed (Table 2). The strongest linear
relationships (r2 > 0.95) are evident for IL-8, with hypoxic
expression levels generally higher than normoxic (m =
0.9627, b = 569.1), and PDGF-AA, with lower levels in
hypoxia (m = 0.8322, b = -1.859). Strong correlations (r2
> 0.80) existed for a number of growth factors (all express-
ing similar levels under hypoxia and normoxia condi-
tions), including: EGF (m = 0.9497, b = -70); TGF-β2 (m
= 0.9632, b = 22.65); and PDGF-AA/BB (m = 1.015, b =
3.74). One anti-angiogenic factor, IP-10, also had a strong
linear correlation, with hypoxic expression levels lower
than normoxic (m = 0.8778, b = -27.55). Moderate corre-
lations (r2 > 0.60) were observed for VEGF, with higher
Culture growth is comparable under normoxic and hypoxic  conditions Figure 1
Culture growth is comparable under normoxic and 
hypoxic conditions. A linear regression of the normoxic 
versus hypoxic percent confluency of each of the 50 samples 
in the study shows the confluencies to be similar within a 
given sample. Many samples reached 100% confluency in both 
conditions, so less than 50 points appear on the graph.
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levels in hypoxia (m = 1.174, b = 552.2), and TGF-β1 (m
= 0.6186, b = 194.7), with lower levels in hypoxia than
normoxia. Linear correlations did not exist for bFGF or
TGF-β3 (r2 < 0.25). Data for Flt-3 ligand was not evalua-
ble, as only six of 50 samples had evaluable results.
RANTES, tested in six samples, indicated similar expres-
sion levels for both conditions (y = 1.0411x+0.0807 and
r2 = 0.9924) suggesting that the changes noted in the other
cytokines were due to hypoxia.
Hypoxia-induced expression of VEGF is tissue-type 
dependent
For VEGF, 46 of 50 samples exhibited higher expression
levels in the hypoxic condition than in the normoxic con-
dition. Since VEGF is the angiogenesis-related factor spe-
cifically implicated in the mechanism of action of
bevacizumab, this data was further analyzed by tissue type
(Figure 2, Table 3). Overall, the combined results of all
cell sources analyzed had a moderate correlation (r2 >
0.60). Breast, lung, and ovarian tumor types had sufficient
sample sizes to sub-analyze by tumor type. While strong
linear correlations were observed for breast and lung sam-
ples (r2 > 0.80), a linear correlation between hypoxic and
normoxic expression of VEGF in ovarian samples did not
exist (r2 < 0.25). Linear correlations were not available for
CNS, colon and unknown primary tumors or for the cell
lines, as samples sizes were too low to assess linearity.
Differential expression of angiogenesis-related factors 
across patient samples
A heat-map of the differences between hypoxic and nor-
moxic expression indicates expression levels of angiogen-
esis-related factors differed both within and between
patients (Figure 3). This data was specifically sorted by
VEGF expression from lowest to highest difference for a
visual representation of the heterogeneous expression lev-
els. Pearson correlation coefficients were also calculated
for all nine angiogenesis-related factors with evaluable
data in relationship to VEGF (data not shown). The Pear-
son correlation coefficients were all less than 0.5, indicat-
ing differences in the other angiogenesis-related factors
are not correlated to differences in VEGF expression.
Together, these data reinforce the idea that differential
angiogenesis-related protein expression levels exist for
each sample.
Discussion
This study addressed a number of topics related to the
expression of angiogenesis-related factors in normoxic
versus hypoxic environments. Specifically, (1) linear cor-
relations exist for a number of angiogenesis-related fac-
tors, (2) linear correlations for VEGF exist and group by
tumor type, and (3) primary expression levels vary
between samples and across factors.
Linear correlations between protein expression in nor-
moxic and hypoxic environments exist for eight of the
eleven angiogenesis-related factors tested in this study
(Table 2). Hypoxic expression levels were generally higher
Table 2: Linear correlations between normoxic and hypoxic growth conditions of angiogenesis-related factors.
Analyte n Slope 
(m)
95% CI Slope (m) y-intercept 
(b)
95% CI y-
intercept
r2
VEGF 50 1.174 0.9049 to 1.443 552.2 98.99 to 1005 0.6163
bFGF 27 0.0813 -0.06828 to 0.2309 82.38 50.21 to 114.5 0.0478
IL-8 33 0.9627 0.9076 to 1.018 569.1 2.366 to 1136 0.9761
EGF 22 0.9497 0.8266 to 1.073 -70 -357.1 to 217.1 0.9283
PDGF-AA 48 0.8322 0.7925 to 0.8720 -1.859 -20.92 to 17.21 0.9748
PDGF-AA/BB 21 1.015 0.8348 to 1.196 3.74 -102.7 to 110.1 0.8793
IP-10 35 0.8778 0.7738 to 0.9817 -27.55 -292.3 to 237.1 0.8995
TGF-β1 45 0.6186 0.4914 to 0.7458 194.7 93.33 to 296.1 0.6913
TGF-β2 47 0.9632 0.8808 to 1.045 22.65 -226.8 to 272.1 0.9251
TGF-β3 27 0.2433 -0.1484 to 0.6350 23.36 10.64 to 36.07 0.0615
Table 3: Linear correlations of VEGF between normoxic and hypoxic conditions.
VEGF Results n Slope 
(m)
95% CI Slope y-intercept
(b)
95% CI y-
intercept
r2
Breast 10 1.316 0.8360 to 1.795 206.1 -262.5 to 674.7 0.8334
Lung 15 1.193 0.9280 to 1.458 178.1 -422.0 to 778.3 0.8793
Ovary 13 0.6432 -0.3679 to 1.654 1458 58.40 to 2858 0.1513
All Samples 50 1.174 0.9049 to 1.443 552.2 98.99 to 1005 0.6163Cancer Cell International 2008, 8:11 http://www.cancerci.com/content/8/1/11
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than normoxic for IL-8 (r2 > 0.95) and VEGF (r2 > 0.60),
though only modestly. Both of these factors are expressed
to induce vascular growth due to hypoxia in vivo, and
appear to do the same in vitro. The degree of difference was
surprising, as both IL-8 and VEGF have been reported to
be up-regulated in response to hypoxic conditions. IL-8
regulates angiogenesis by promoting survival of endothe-
lial cells, stimulating matrix metalloproteinases, and
increasing endothelial permeability [15,16]. VEGF is a
major signalling protein for angiogenesis secreted in
higher levels when cells experience hypoxia [4]. IP-10, an
anti-angiogenic factor, had lower expression levels in the
hypoxic condition than in the normoxic condition (r2 >
0.80). This was expected, as this protein inhibits tumor
growth by regulating lymphocyte chemotaxis and inhibit-
ing endothelial growth [21].
Trends in the expression levels of other growth factors
were variable. Lower expression levels were observed in
the hypoxic condition for PDGF-AA (r2 > 0.95) and simi-
lar levels were observed for PDGF-AA/BB (r2 > 0.80).
These results are not surprising as platelet populations are
minimal in culture. These cells are non-adherent to flask
surfaces and are rinsed away during routine media
changes. Different results were observed for each of the
transforming growth factors, likely related to the specific
role each plays in cancer pathogenesis [18]. Lower expres-
sion levels were observed in the hypoxic condition for
TGF-β1, while similar expression levels were observed in
both conditions for TGF-β2 (r2 > 0.80) and no correlation
existed for TGF-β3 (r2 < 0.25). Similar expression levels
were observed in both conditions for EGF, which may be
due to the fact that EGF induces VEGF, IL-8, and bFGF
release by tumor cells, and is transformed in the process
[9]. A correlation did not exist for bFGF, which mediates
VEGF production and induces extracellular matrix forma-
tion. Another in vitro study showed bFGF was unaffected
by hypoxia in cell lines [3]. In all, the correlations between
the conditions in vitro suggest the expression levels may be
linked to in vivo expression of each angiogenesis-related
factor, whether measured in normoxic or hypoxic condi-
tions.
The combined results of all cell sources analyzed for VEGF
showed a moderate correlation between normoxic and
hypoxic expression levels. Stronger linear correlations
were observed for breast and lung samples specifically.
Breast and lung samples are cultured in unique culture
Linear correlations between normoxic and hypoxic conditions exist for VEGF and group by tumor type Figure 2
Linear correlations between normoxic and hypoxic conditions exist for VEGF and group by tumor type. Fifty 
cell sources (45 primary tumor cultures and 5 immortalized cell lines) were evaluated for VEGF expression measured by 
ELISA-based assay. Linear correlations exist between cells grown in normoxic and hypoxic conditions (Table 2). The larger 
graph divides the specimens by tumor type, while the inset combines all data sets.
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media as compared to ovarian, CNS, and colon samples.
Primary breast tumors are cultured in Mammary Epithe-
lial Growth Media (MEGM), while lung tumors are cul-
tured in Bronchial Epithelial Growth Media (BEGM).
These media require addition of SingleQuots® to basal
media that include EGF. Significantly, EGF induces VEGF,
IL-8, and bFGF release by tumor cells [9]. While this Sin-
gleQuots® may have contributed to the VEGF production
in these tumor types, the other analytes (IL-8 and bFGF)
induced by EGF did not correlate by tumor type (data not
shown). Therefore, culture media is probably not respon-
sible for the differential expression levels of the ten evalu-
able angiogenesis-related proteins and a unique
fingerprint for each sample. In general, these data suggest
in vitro expression levels of VEGF can be measured in
either a normoxic or a hypoxic condition, since a linear
correlation exists between expression levels in both condi-
tions.
Differential protein expression levels existed for each fac-
tor tested in this study, as is evident in Figure 3. In vitro
studies show differential degrees of primary tumor
response to chemotherapy agents. These response rates
correlate with progression-free interval in ovarian cancer
patients, which indicates in vitro tests performed on pri-
mary cultures may be used to enhance the probability of
choosing the best treatment regimen for the patient [24].
Similarly, differential protein expression levels were
observed across patients in this study for each of the fac-
tors. This suggests it may be possible to build a predictor
for angiogenesis-related anticancer agents using an array
of protein expression levels observed in vitro.
There are limits to the application of these in vitro results
to the in vivo condition. The tumor microenvironment in
vivo is unique both in its three-dimensional structure and
the chemical environment [25]. This affects cellular
behaviour, including response to chemotherapeutic
agents. Some researchers have successfully developed cul-
ture systems that replicate this three-dimensional interac-
tion of cells [26]. This study, however, employed a
monolayer culture system specifically designed to enrich
the population of malignant epithelial cells [27]. While
toxicity, delivery, metabolism, and clearance affect patient
response to therapeutics in vivo, in vitro studies are com-
monly used in initial testing of novel treatments and have
clinical potential when applied [28].
Although extreme hypoxic conditions may compromise
the health of the cells and lead to cell death, similar con-
fluencies between the normoxic and hypoxic condition at
the conclusion of testing suggest that the 48 hour incuba-
tion prior to testing was sufficient for cell adherence and
equilibration (Figure 1). To support this observation,
Pilch et al. found that hypoxia did not cause cell death/
Differential expression of angiogenesis-related factors is evi- dent across samples Figure 3
Differential expression of angiogenesis-related fac-
tors is evident across samples. Differential levels of 
expression are evident across all patients for the angiogen-
esis-related factors tested. Bright red indicates lowest 
expression level difference, bright blue indicates highest 
expression level difference, and white indicates no data. Cor-
relation coefficients indicate the differences in VEGF are not 
correlated to differences in expression of the other angio-
genesis-related proteins.
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decreased confluency, as dead cells were not observed in
supernatant post-hypoxia [1]. Furthermore, the hypoxic
oxygen concentration used in the study in vitro is similar
to that reported by Hockel and Vaupel, 2001, in the core
of solid tumors in vivo [29].
Also, in addition to the 11 angiogenesis-related analytes
chosen for testing, a negative control unrelated to angio-
genesis was also assessed. A chemotactic cytokine,
RANTES, is responsible for recruiting leukocytes and acti-
vating natural killer cells [23]. This cytokine was not
expected to vary in a normoxic versus hypoxic environ-
ment, and we found similar expression levels of RANTES
for both conditions validating our technical approach.
Multiple techniques are available to assess VEGF expres-
sion. Some laboratories employ immunohistochemical
(IHC) analysis to determine VEGF receptor levels [5], usu-
ally for diagnostic and prognostic purposes. However, this
study employed the Beadlyte® CytokineProfiler™ Testing
Service for two reasons. First, this service provides quanti-
tative analysis of the expression levels of the angiogenesis-
related factors, including VEGF. Second, testing was per-
formed on malignant epithelial cell cultures, rather than
tissue sections. Intact tissue sections that contain tumor
cells as well as support tissue and vasculature are generally
stained using IHC. VEGF receptors on endothelial cells
and monocytes fluoresce. The described culture process
selects specifically for malignant epithelial cells [27].
Endothelial cells are selected against by culture condi-
tions, as the media employed do not promote the growth
of these cells; monocytes are non-adherent, so are rinsed
away in routine media changes [27]. Neither of these cell
types is present in the described samples so IHC of the
VEGF receptors was not possible.
VEGF production was of most interest to this study due to
its role in the mechanism of action of bevacizumab. The
testing conditions were optimized to ensure that VEGF
production was measurable, so VEGF results were availa-
ble for all samples tested. Table 3 includes the summary
of all data in the "All Samples" field, a total of 50 samples.
Results for the other ten analytes had detection levels out
of range of the standard curve for at least two samples, if
not more. As a result, the sample size for most of these
angiogenesis-related factors was less than 50 (Table 2).
However, nine of these ten factors had at least 20 samples
available for analysis, and were considered evaluable in
the study.
As with any anticancer therapeutic agent, there is clinical
ambiguity regarding individual patient response. Some
agents directly target VEGF, such as bevacizumab, a
humanized monoclonal antibody, while others indirectly
target receptors and downstream regulators, such as
sunitinib and rituximab [8]. While the regulation and
metabolism are unique in vivo, the protein expression lev-
els produced by individual patient cells may provide
information on how each patient will respond clinically
to a given anticancer agent. The heterogeneity of protein
expression demonstrated in this study may provide infor-
mation to enable the prediction of the efficacy of anti-ang-
iogenic factors. Further studies correlating the in vitro
expression levels with patient outcome are warranted.
Conclusion
Linear correlations exist between expression levels of ang-
iogenesis-related factors under normoxic and hypoxic
conditions. This suggests the behaviour of primary cells
derived from patient tumors grown under in vitro nor-
moxic conditions may provide a correlation to the in vivo
hypoxic environment. Differential expression for each
sample across all factors suggests predictive value for ang-
iogenesis-related anti-cancer agents, using not only VEGF,
but an array of angiogenesis-related proteins. These data
suggest further studies should be considered to correlate
in vitro expression of these proteins with in vivo patient
response to anti-angiogenesis therapeutics.
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